What's new {#Sec1}
==========

Cardiotoxicity related to cancer therapy is of rising concern since it negatively impacts the prognosis. The 2016 European Society of Cardiology guideline described updated standard therapies for acquired long QT syndrome (ALQTS) associated with cancer therapy. However, evidence-based data regarding ALQTS in hospitalized cancer patients is limited.

Clinical implications {#Sec2}
=====================

In our study cohort, markedly prolonged QT interval was seen in 1.5% of hospitalized cancer patients. The all-cause mortality was high in cancer patients with severe ALQTS.

Introduction {#Sec3}
============

With advances in early detection and therapeutics, the cancer survival rate continues to rise worldwide. Cancer survivors, nevertheless, are susceptible to cardiovascular diseases and cardiotoxicity of cancer drugs \[[@CR1], [@CR2]\]. Cardiovascular disorder is a major cause of morbidity and mortality in cancer survivors \[[@CR3]\]. These patients are prone to various types of arrhythmias, including tachycardias, bradycardias and conduction disorders \[[@CR4], [@CR5]\]. Sometimes cardiac arrhythmias can be life-threatening \[[@CR6]\]. In this regard, QT prolongation caused by acquired factors associated with cancer therapeutics, termed Acquired Long QT Syndrome (ALQTS), is a key risk state that has been long overlooked in both cardiology and oncology. Using the Pro-QTc score in an institution-wide QT alert system could help identify the high-risk of mortality with markedly prolonged QT interval (QTc ≥ 500 ms). In 2017, our group reported cancer to be one of the major factors associated with all-cause mortality in ALQTS \[[@CR7]\]. Thus, this study aimed to investigate the impact of ALQTS on the prognosis in hospitalized cancer patients. A priori, we hypothesized that the outcome of cancer patients with ALQTS would be poor, affected by various clinical factors.

Materials and methods {#Sec4}
=====================

Study population {#Sec5}
----------------

In this matched case-control study, we retrospectively enrolled hospitalized cancer patients with severe ALQTS from September 2013 to April 2016 in the First Affiliated Hospital of Dalian Medical University. Study population was separated into ALQTS group and control group. The inclusion criteria for the ALQTS group were: Hospitalized cancer patients (age \> 18 years) from Hematology-Oncology or other departments showing QTc (Bazett's) ≥ 500 ms without a family history of inherited LQTS, unexplained syncope, cardiac arrest, or sudden death. The exclusion criteria included QRS duration \> 120 ms, presence of complete left or right bundle branch blocks, intraventricular conduction delays or ventricular pacing. Moreover, ECG showing atrial fibrillation/flutter, second-degree and complete atrial-ventricular blocks, severely sinus, atrial and ventricular tachyarrhythmia, and acute coronary syndrome with dynamic ST-T that interfered accurate QT assessment were excluded. The inclusion criteria for the control group were same as the ALQTS group, except all had a normal QT interval (350 ms \< QTc ≤ 440 ms) during hospitalization. The age, sex and the cancer diagnosis were comparable between ALQTS and control groups. This study was approved by the Ethics Committee of the First Affiliated Hospital of Dalian Medical University.

ECG evaluation {#Sec6}
--------------

According to the inclusion and exclusion criteria, we retrieved electronic records of standard resting 12-lead ECG parameters from the Muse System (7.1.1 edition), including heart rate (HR) and QTc. ECG were recorded with a paper speed of 25 mm/s and voltage of 10 mm/1 mV in the supine position, using GE Healthcare MAC 5500 ECG diagnosis systems (India). If differences in the QTc interval exceeded 20 ms between the machine and hand measurement, the interval was corrected manually, especially in cases with complex T wave morphologies. In these cases, QT intervals were measured by an experienced QT investigator from lead II, V5 or the lead with the longest QT interval. If several ECG recordings during hospitalization were available, the longest QTc was selected.

Clinical evaluation {#Sec7}
-------------------

From the electronic medical records, we retrieved data including cancer diagnosis, classification and staging, medical history, chemotherapy drugs and presence of QT-prolonging factors such as electrolyte disorders and use of QT-prolonging drugs. Laboratory tests taken within 48 h before or after ECG recording were evaluated, including serum potassium (normal range 3.5--5.3 mmol/L) and serum calcium (2.02--2.6 mmol/L). QT-prolonging drugs used within 7 days of the ECG evaluated in this study were screened through the website (<https://www.crediblemeds.org>).

Follow-up {#Sec8}
---------

In this study, all-cause death was determined as research endpoint. Telephone survey was conducted after permission obtained from study participants or their legally authorized representatives. When death had occurred, the possible causes were investigated.

Application of the pro-QTc score system {#Sec9}
---------------------------------------

We employed the Pro-QTc Score to explore the risk of death in patients with QTc ≥ 500 ms. QT-prolonging diagnoses and conditions include cardiomyopathy, acute coronary syndrome, prolonged QT interval, congestive heart failure, bradycardia, diabetes mellitus, stroke, hypokalemia, hypocalcemia, hypomagnesemia, female gender, old age, and several QT-prolonging drugs, which have been compiled in the QT drug list by the Arizona Center for Education and Research on Therapeutics (AZCERT). Each measure in the score system was scaled as 1 point \[[@CR8]\]. Pro-QTc scores ≥4 were considered predictive of high mortality risk.

Statistical analyses {#Sec10}
--------------------

Continuous data were expressed as mean ± SD, and comparative analysis was performed by Student's *t*-tests for independent samples. The Mann-Whitney *U* Test was applied when variables were non-normal distributions. Categorical variables were expressed as absolute (n) and relative proportions (%), and were analyzed using the *χ*^2^ (Chi-square) test. 2-tailed statistical significance was considered when *p* \<  0.05. Multivariate logistic regression was performed to calculate odds ratios (OR) for various predictors of QT prolongation. For this procedure, variables were selected on the following based on clinical relevance and presence of *p* values \< 0.1 in univariate analysis. The univariate cumulative probability of all-cause mortality during hospital stay and up to 2-year follow-up was assessed by the Kaplan-Meier survival curve using Log-rank statistics. The Cox proportional hazard survival model was used to evaluate the effect of clinical factors on the endpoint. Statistical analyses were performed using SPSS software (version 22.0, SPSS Inc., Chicago, IL).

Results {#Sec11}
=======

Incidence of severe ALQTS in hospitalized cancer patients and their clinical characteristics {#Sec12}
--------------------------------------------------------------------------------------------

Between September 2013 and April 2016, we identified 200 subjects with ALQTS from a total of 10,180 cancer patients hospitalized in the hematology-oncology departments. After applied exclusion criteria and manually checking QT measurement performed by experienced QT investigators, 150 ALQTS patients remained in the study. Compared with age, sex, and cancer type matched 293 non-ALQTS patients, the incidence of hospitalized cancer patients with severe ALQTS was 1.5% (150/10180).

As to the cancer diagnosis in this study cohort, hematological cancer accounted for 25%, lung cancer 21%, gastrointestinal cancer 20%, breast cancer 17%, gynecologic cancer 7%, urological cancer 3%, prostate cancer 1%, and other cancers 5%. The baseline characteristics of the ALQTS and non-ALQTS groups was summarized in Table [1](#Tab1){ref-type="table"}. Table 1Clinical characteristics in hospitalized malignant cancer patients with and without severe ALQTSECG and clinical aspectsALQTS\
(*n* = 150)Non-ALQTS\
(*n* = 293)*p* valueAge (years)62 ± 1362 ± 130.331Gender Female58%58%0.887 Male42%42%Comorbidities Hypertension29.3%16.4%0.001 Heart Failure6.7%0.7%\<  0.001 Arrhythmia6.7%2.7%0.047 Renal Insufficiency5.3%2.7%0.165 Infection21.3%5.1%\<  0.001 Type 2 mellitus16.0%9.6%0.046 Neurologic diseases10.7%3.4%0.002 Anemia12.0%1.4%\<  0.001ECG DataHeart rate (bpm)88 ± 1772 ± 12\<  0.001QTc (ms) φ520 (20)422 (18)\<  0.001Laboratory Test Hypokalemia31.7%5.2%\< 0.001 Hypocalcemia22.7%4.9%\<  0.001MedicationsQT-prolonging drugs31.3%6.8%\<  0.001Chemotherapeutic drugs Anti-microtubule agents36%28%0.084 Platinum34%31.1%0.530 Antimetabolites33.3%27.3%0.187 Alkylating agents29.1%17.7%0.215 Anthracyclines28%28.1%0.151 Arsenic trioxide2%1.4%0.612Values are expressed as mean ± SD or median (interquartile range) unless otherwise indicated. φ Median (inter-quartile range) is shown. *Abbreviations*: *ALQTS* acquired long QT syndrome, *ECG* electrocardiograph

Outcomes and risk factors for QT-prolongation in hospitalized cancer patients with severe ALQTS {#Sec13}
-----------------------------------------------------------------------------------------------

Kaplan-Meier analysis shows that cancer patients with severe ALQTS had much higher all-cause mortality (Fig. [1](#Fig1){ref-type="fig"}) compared to age-, sex- and cancer diagnosis-matched hospitalized cancer patients with normal QT intervals (63.3% vs. 33.4%, *p* \<  0.001). Clinical factors associated with QT prolongation in our study cohort are shown in Table [2](#Tab2){ref-type="table"}. Fig. 1Kaplan-Meier Survival Curve in Hospitalized Patients with and without Severe ALQTS. Kaplan-Meier analysis shows that cancer patients with severe ALQTS had much higher all-cause mortality. Abbreviations: ALQTS, acquired long QT syndrome Table 2Clinical factors associated with QT prolongation in hospitalized cancer patients\*VariablesOR (95%CI)*p* valueHypertension2.433 (1.319--4.489)0.004Infection3.456 (1.471--8.121)0.004Anemia4.879 (1.325--17.961)0.017Hypokalemia6.271 (3.007--13.080)\<  0.001Hypocalcemia2.360 (1.028--5.445)0.043QT-prolonging drugs5.083 (2.544--10.155)\<  0.001Anti-microtubule agents2.857 (1.658--4.925)\< 0.001\*Using multiple logistic regression analysis. *Abbreviations*: *OR* odds ratio, *CI* confidence interval

QT-prolongation and chemotherapeutic drugs {#Sec14}
------------------------------------------

As shown in Tables [1](#Tab1){ref-type="table"}, 31.3% of patients in the ALQTS group used QT-prolonging drugs, including diphenhydramine (26%), famotidine (23%), quinolone antibiotics (21%), and furosemide (19%). Additionally, there were no significant differences among chemotherapeutic drugs between the ALQTS and non-ALQTS groups.

Clinical characteristics and all-cause mortality contributors between non-survivors and survivors in hospitalized cancer patients with severe ALQTS {#Sec15}
---------------------------------------------------------------------------------------------------------------------------------------------------

Comparisons between survivors and non-survivors in the ALQTS group are presented in Table [3](#Tab3){ref-type="table"}. Multivariable Cox regression was performed between non-survivors and survivors in hospitalized cancer patients with severe ALQTS (Table [4](#Tab4){ref-type="table"}). The Cox proportional hazard survival model revealed that male (HR 1.643, 95%CI 1.023--2.640, *p* = 0.040), renal insufficiency (HR 5.358, 95%CI 1.984--14.473, *p* = 0.001), and hypokalemia (HR 2.315, 95%CI 1.417--3.781, *p* = 0.001) were major contributors to all-cause mortality. Table 3Clinical characteristics in hospitalized cancer patients with severe ALQTS between Non-survivors and survivorsParametersNon-survivors\
(*n* = 95)Survivors\
(*n* = 55)*P* ValueAge, years66 ± 1056 ± 140.000 ≥ 70 years36.8%18.2%0.016Gender Female49.5%72.7%0.005 Male50.5%27.3%HR, bpm90 ± 1985 ± 120.062QTc, ms5135090.243Hypokalemia40.4%17%0.004Hypocalcaemia26.1%17%0.209Use of QT-prolonging drugs36.4%28.4%0.312Renal insufficiency8.4%0.0%0.027Infection26.3%12.7%0.05Anemia15.8%5.5%0.061Arrhythmia5.3%9.1%0.365Heart Failure7.4%5.5%0.651Hypertension29.5%29.1%0.96*Abbreviations*: *ALQTS* acquired long QT syndrome, *HR* heart rate Table 4Cox proportional hazard survival between non-survivors and survivors in the severe ALQTS groupUnivariate analysisMultivariate analysisHR (95%CI)*P* valueHR (95%CI)*P* valueMale1.793(1.198--2.682)0.0051.643(1.023--2.640)0.040Age ≥ 70 years1.595 (1.051--2.420)0.0281.034 (0.624--1.715)0.896Pro-QTc ≥ 4 score1.839 (1.155--2.929)0.0101.090 (0.561--2.116)0.799Hypokalemia2.403 (1.565--3.689)\< 0.0012.315 (1.417--3.781)0.001Hypocalcemia1.833 (1.136--2.959)0.0131.258 (0.697--2.272)0.446Renal failure4.405 (2.097--9.252)\<  0.0015.358 (1.984--14.473)0.001Infection1.970 (1.243--3.123)0.0041.423 (0.854--2.373)0.176Anemia2.388 (1.367--4.169)0.0021.717 (0.837--3.523)0.140*Abbreviations*: *ALQTS* acquired long QT syndrome, *HR* Hazard Ratio, *CI* confidence interval

Application of the pro-QTc score {#Sec16}
--------------------------------

In our study, we applied the Pro-QTc score, proposed by the Mayo Clinic. Figure [2](#Fig2){ref-type="fig"} shows the Pro-QTc scores of patients with severe ALQTS. A significant difference was found between non-survivors and survivors in the group with severe ALQTS group in univariate Cox hazard survival model; however, no difference was ascertained after multivariate adjustment (Table [4](#Tab4){ref-type="table"}). Fig. 2Pro-QTc score in patients with severe ALQTS. There were no significant/statistical difference between two groups. Abbreviations: ALQTS, acquired long QT syndrome

Discussion {#Sec17}
==========

In this study, we found that severe ALQTS (QTc ≥ 500 ms) accounts for 1.5% of cancer patients for in-hospital treatment. Among cancer patients, the all-cause mortality is significantly higher in those with ALQTS than those without QTc prolongation. Generally, ALQTS subjects are more severe than those with normal QTc interval (Table [1](#Tab1){ref-type="table"}), with higher frequency of electrolyte imbalances, more use of QT-prolonging drugs and more patients suffering from cancer-related infections, anemia, and concomitant diseases.

Severe ALQTS in hospitalized patients is seen 0.7% as we reported previously \[[@CR7]\]. The prevalence of severe ALQTS in cancer patients revealed in this study is 2-fold (1.5%) higher indicating delayed ventricular repolarization is much more profound among cancer patients. This finding, however, does not necessarily mean that cancer is a direct cause of QT prolongation. The higher prevalence of ALQTS in cancer patients is likely contributed by 1) presence of QT-prolonging electrolyte imbalance such as hypokalemia and hypocalcaemia (Table [1](#Tab1){ref-type="table"}); 2) use of QT-prolonging drugs; 3) baseline conditions such as hypertension. Most of cancer patients were elders and many had a history of hypertension. Left ventricular hypertrophy resulted from hypertension is a major cause of ALQTS \[[@CR9], [@CR10]\]. Chemotherapy can impair immune system. Thus, post-chemotherapy patients are prone to infections. Infection with inflammatory environment can prolong QT interval due to the effect of inflammatory cytokines (interleukin-6, tumor necrosis factor-α, interleukin-1) on potassium and calcium channels \[[@CR11]--[@CR14]\]. QT-prolonging antibiotics such as quinolone antibiotics are commonly prescribed in cancer patients. Anemia is very common in cancers patients especially in late stage. The decreased hemoglobin level can cause tachycardia-cardiomyopathy and increased myocardium mass is associated with QT prolongation \[[@CR15]--[@CR17]\].

As demonstrated in Table [1](#Tab1){ref-type="table"} cancer patients with severe ALQTS are generally sicker than those without ALQTS. Thus, it is in no surprise that they had a poor outcome measured by a significantly higher all-cause mortality (Fig. [1](#Fig1){ref-type="fig"}). In this study, we found that renal insufficiency is one of the contributors to all-cause mortality in cancer patients with ALQTS. Hypokalemia is common in patients with renal insufficiency immediately post dialysis and in patients using potassium-loss diuretics. Therefore, on the basis of previous and our study, we speculate that eliminating the use of QT-prolonging medications and monitoring modifiable QT-prolonging risk factors such as management of electrolyte disturbance are beneficial for prognosis especially in cancer patients with severe ALQTS.

The application of chemotherapeutic drugs is indispensible and complex in cancer patients. Anthracyclines (doxorubicin) \[[@CR18]\], arsenic trioxide \[[@CR19]\] vandetanib \[[@CR6], [@CR20]\] and molecular-targeted drugs \[[@CR21]--[@CR24]\] have been confirmed to prolong the QTc interval. As shown in Table [1](#Tab1){ref-type="table"}, our study showed that, except for anti-microtubule agents which has been reported to be linked to QTc prolongation \[[@CR25], [@CR26]\], the rest of chemotherapeutic QT-prolonging drugs are not statistically significant in our study. The insignificance may be related to the small number of patients in terms of each cancer drug used.

In this study, Pro-QTc score ≥ 4 \[[@CR7]\] failed to predict the all-cause mortality in cancer patients. It is perhaps that Pro-QTc was designed to pick up risk factors of sudden arrhythmic death. Most of our non-survival cancer patients died of cancer itself. Prolonged QT interval may reflect the disease severity rather than the direct cause of death in most of cancer non-survivors. Nevertheless, most of QT-prolonging factors are modifiable. Further study is warranted to determine whether eliminating certain risk factors exerts influence on patient outcomes. Establishing an accurate evaluation model to predict mortality risk in cancer patients with ALQTS is urgent.

Limitation {#Sec18}
----------

Our findings should be interpreted in the context of the following limitation. Study outcomes were defined as all-cause mortality in this retrospective study, with limited electrophysiological data after patients discharged from hospital. Because of the use of telephone follow-up, specific causes of death cannot be obtained and data analysis related to cardiovascular death is lacking. Further studies are required to examine the effect of ALQTS on the sudden death in hospitalized cancer patients.

Conclusions {#Sec19}
===========

Markedly prolonged QTc interval was seen in 1.5% of hospitalized cancer patients. The all-cause mortality was high in cancer patients with severe ALQTS.

ALQTS

:   Acquired long QT syndrome

CI

:   Confidence interval

HR

:   Heart rate/Hazard ratio

OR

:   Odds ratio
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